Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care54
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia54
Arguments for and against extending the interval between colonoscopies following negative results in colorectal cancer screening33
Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach32
Molecular-driven treatment for biliary tract cancer: the promising turning point31
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)29
A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer27
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence25
Strategies for the prevention or reversal of PARP inhibitor resistance23
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial19
Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer19
Emerging immune-based technologies for high-grade gliomas19
What influence does mammographic density have on breast cancer occurrence?19
Lymph nodal radiotherapy in breast cancer: what are the unresolved issues?19
Avelumab in locally advanced or metastatic urothelial carcinoma18
Low CBS expression can identify patients who benefit from adjuvant chemotherapy in gastric cancer17
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer17
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?17
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients17
0.19843292236328